LSE:GSK 16 June 2026 - 6 July 2026

GSK stock rises as £80 billion valuation shifts focus to oncology delivery
·

GSK stock rises as £80 billion valuation shifts focus to oncology delivery

GSK plc rose on Tuesday, but the more useful number for investors was not the one-day gain. It was the gap between the share price and the Street model. At 1901 BST, after the London Stock Exchange regular session that runs from 0800 to 1630 BST, Davy’s delayed feed showed GSK at 2,003p, up 20p, or 1.01%, with a 1,982p-2,031p day range. The FTSE 100 closed up 0.1% at 10,655.88 points.
July 7, 2026
FTSE 100 edges lower as deal risk holds easyJet bid gap
···

FTSE 100 edges lower as deal risk holds easyJet bid gap

London trade was done for the day at this point; the LSE runs from 0800 to 1630 BST on weekdays. The decline wasn't across the board. Losses in several bigger names weighed on the index, but some deal names and banks limited the drop. The FTSE 100 ended down 27.26 points at 10,651.77, according to market-data streams. The index hit 10,733.39 earlier in the day but finished around 2.6% under its all-time high from February 2026 at 10,934.94. It's still up 20.95% over the last year.
July 6, 2026
GSK (LON:GSK) rises Friday, eyes on July 28 results for sales gap check
·

GSK up after HSBC upgrade, £5 bln sales gap still seen

GSK plc traded higher in London on Monday after HSBC Holdings plc boosted its rating. The bank’s upgrade gave the shares a lift, but analysts’ sales estimates are still well short of the company’s 2031 goal. GSK traded at 2,025p, up 10p or 0.5% from the last close, according to MarketWatch at 13:47 BST. Shares are still down about 11% from the 52-week high of 2,282p hit in February, but have gained 45.1% in a year.
July 6, 2026
GSK (LON:GSK) rises Friday, eyes on July 28 results for sales gap check
·

GSK (LON:GSK) rises Friday, eyes on July 28 results for sales gap check

GSK plc finished the week at 2,015p, closing at the top of its range for the past month. Shares jumped 3.83% on Thursday, then added another 0.55% on Friday. Market cap closed around £80.71 billion. GSK showed a P/E ratio of 11.65 and dividend yield of 3.28%, according to Hargreaves Lansdown. Investors shouldn’t just look at GSK’s weekly gain. The move came in the pattern of trading. GSK tracked the FTSE 100 for most of the week, but Thursday saw about a third of the five-day volume. Friday volume dropped to 2.55 million shares, down 76% from the week’s average.
July 4, 2026
GSK (LON:GSK) bounces, market looks at buyback ahead of Nuvalent cutoff
·

GSK (LON:GSK) bounces, market looks at buyback ahead of Nuvalent cutoff

GSK plc shares bounced Thursday, with a UK retail broker’s page quoting them at 2,011p to sell and 2,012p to buy after closing at 1,930p. That’s roughly 4.2% higher at the midpoint against Wednesday’s close. The FTSE 100 finished up 1.67% at 10,652.87. The gain wiped out Wednesday’s loss, when GSK dropped 2.57% to finish at £19.30. Volume was 5.4 million shares, under its 50-day average of 8.0 million. The stock closed that day 15.43% below its 52-week high of £22.82 hit on Feb. 18.
July 2, 2026
FTSE 100 edges up, but UK mid-caps slide after credit worries
······

FTSE 100 edges up, but UK mid-caps slide after credit worries

The FTSE 100 edged higher late Thursday morning, but the main story was away from the headline number. Trading Economics showed its FTSE 100 GB100 CFD at 10,528.33, up 0.48%. But Sharecast’s 0834 BST snapshot had the FTSE 100 off 0.07% at 10,470.93 and the FTSE 250 0.58% lower at 23,194.67. Early moves showed small caps got hit harder on guidance. Sharecast’s table said the 10 worst FTSE 250 names dropped an average 4.10%. That compares to a 1.46% average drop for the 10 worst FTSE 100 stocks. The biggest FTSE 100 gainers rose an average 1.76%. Food retail, luxury and exchange infrastructure names led on the upside.
July 2, 2026
GSK slip wipes out most of 2026 payout with sales still limited
·

GSK slip wipes out most of 2026 payout with sales still limited

c dropped more than the main London indexes on Wednesday, with the move lining up against its own dividend outlook. Shares lost 51p, nearly 73% of the 70p dividend GSK has forecast for 2026. The stock didn’t find much support from the usual defensive income trade. GSK closed with a bid of 1,934.5p and offer of 1,935.5p according to Hargreaves Lansdown, 2.57% lower on the day. The FTSE 100 slipped 0.18%. Reuters said healthcare stocks lost 1.6%, GSK dropped about 2.5% and AstraZeneca PLC fell 1.7%.
July 1, 2026
FTSE 250 outpaces FTSE 100 as domestic and defence names help London market
········

FTSE 250 outpaces FTSE 100 as domestic and defence names help London market

FTSE 250 outperformed the FTSE 100 on Wednesday as mid-caps climbed 1.38% to their highest in a week. The FTSE 100 slipped 0.18%, weighed down by declines in healthcare and oil heavyweights. Regular London trading hours were 0800 to 1630 local, as usual. The spread suggested the trade was cleaner than the main index let on. Dollar earners in the FTSE 100 with heavy exports got hit by declines in oil and pharma. Domestic and specialist mid-caps saw buyers step in, though the Bank of England offered no signal on rate cuts.
July 1, 2026
GSK plc (LON:GSK) share price: 3% weekly gain puts Nuvalent tender deadline in view
··

GSK ends £2bn buyback with shares near 2,000p; Nuvalent deal in focus

GSK plc edged higher by late morning Tuesday in London. But what mattered more for traders was the price it paid snapping up its own shares, just ahead of the bigger Nuvalent, Inc. agreement grabbing focus. GSK traded at a 1,996.00p sell and 1,996.50p buy on AJ Bell, up 17.00p, or 0.86%. Market value was £79.95 billion. The FTSE 100 added 73.04 points, or 0.70%, to 10,557.26 at 10:34 BST, Investors Chronicle reported, with data at least 15 minutes late.
June 30, 2026
GSK plc (LON:GSK) share price: 3% weekly gain puts Nuvalent tender deadline in view
··

GSK trades close to analyst target after Nuvalent deal

GSK plc traded a bit lower in late London hours on Monday, with the bigger focus for investors on valuation rather than the minor decline. Shares showed a sell price of 1,980.50p and a buy price at 1,981.00p as of 11:46 BST, down 0.13%. The FTSE 100 was down too. Shares are now close to the median analyst target. Investors Chronicle data shows 18 analysts have a median 12-month target of 1,980p, with estimates ranging from 2,750p down to 1,455p. The stock is up 40.91% over the past year, which suggests to some the easier part of the re-rating is probably over.
June 29, 2026
GSK plc (LON:GSK) share price: 3% weekly gain puts Nuvalent tender deadline in view
··

GSK plc (LON:GSK) share price: 3% weekly gain puts Nuvalent tender deadline in view

GSK plc ended a thin news week with a 3% gain, leaving the London-listed drugmaker close to the 2,000p line and giving investors a cleaner read on its biggest question: whether the market is starting to accept an £8 billion oncology bet that looked large for a company long viewed as a vaccines and HIV name. London trading was shut on Saturday. The London Stock Exchange lists June 27 as closed, after a normal Friday session from 8:00 a.m. to 4:30 p.m. BST. GSK’s last London trade was Friday’s 1,983.00p close, down 0.03% on the day, after a 1,945.50p-1,995.50p range.
June 27, 2026
GSK (LON:GSK) ends £2 billion buyback, Nuvalent tender starts
··

GSK (LON:GSK) ends £2 billion buyback, Nuvalent tender starts

GSK plc traded lower in London on Friday. The day marked the final scheduled round of its £2 billion share buyback, but the $10.6 billion Nuvalent tender offer has become a bigger weight than the daily support from the buyback. The London Stock Exchange was open at the dateline time; its June 26 session runs from 0800 to 1630 BST. GSK traded at 1,951.50p on the sell side and 1,952.00p to buy, down 32p, or 1.61%, according to AJ Bell. The stock’s market cap was about £78.21 billion. A £180 million final buyback at these levels would be close to 9.2 million shares, or about 0.2% of the company’s equity. Meanwhile, the Nuvalent bid, valued by GSK at £8.0 billion,
June 26, 2026
GSK shares unchanged as Nuvalent guidance puts pressure on $10.6 billion buyout
··

GSK shares unchanged as Nuvalent guidance puts pressure on $10.6 billion buyout

GSK shares didn’t move much Thursday as the company kicked off its $124-per-share cash tender offer for Nuvalent. New filings from Nuvalent spell out the sales growth GSK needs to make this its biggest purchase in over ten years. Nuvalent is projecting net revenue of $14 million in 2026, climbing to $1.35 billion by 2030 and $2.53 billion for 2031, according to its unaudited, risk-adjusted management forecast. EBIT is negative until 2029, then expected to hit $1.50 billion by 2031. Unlevered free cash flow stays below zero through 2029, then moves up to $275 million in 2030, hitting $936 million in 2031.
June 25, 2026
GSK Stock Slips as Tivicay Priority Review Sets Up Busy FDA Calendar (LSE:GSK)
·

GSK stock holds close to buyback price after seven board members report buys

GSK traded 0.2% higher at 1,961.5 pence by 12:11 BST Wednesday, sitting only 0.53% above the average purchase price in its most recent weekly buyback. New filings revealed seven non-executive directors picked up ordinary shares or U.S.-listed depositary shares. The FTSE 100 was up 0.08%. GSK rose 1.71% Tuesday as the FTSE 100 slipped 0.09%. Volume was light at 4.8 million shares, under the 50-day average of 7.5 million. The stock finished 14.22% off its February 18 peak of 2,282 pence.
June 24, 2026
GSK Stock Slips as Tivicay Priority Review Sets Up Busy FDA Calendar (LSE:GSK)
·

GSK Rises While FTSE Slips as Traders Turn to Pharma

GSK was up 0.6% at 1,936.5 pence as of 12:01 BST Tuesday. Shares moved in a range of 1,911 to 1,944.5 pence. The stock was among the few gainers in a sluggish London market. FTSE 100 drops to lowest since June 12, defensive stocks gain The FTSE 100 was down 0.7% and hit its lowest mark since June 12 earlier as traders pulled back on risk with more rate hikes seen likely. Healthcare and pharma shares picked up more than 1%. The move looked like a defensive play, not something specific to GSK.
June 23, 2026
GSK Stock Slips as Tivicay Priority Review Sets Up Busy FDA Calendar (LSE:GSK)
·

GSK Stock Slips as Tivicay Priority Review Sets Up Busy FDA Calendar (LSE:GSK)

GSK plc shares traded lower on Monday even after its HIV unit secured an accelerated US regulatory review for a wider use of Tivicay. The stock, listed as LSE:GSK, was around 1,914 pence in afternoon dealings, roughly 0.6% below Friday’s close, while the FTSE 100 gained about 0.6%. The muted reaction reflects the size of the immediate opportunity. Extending Tivicay to newborns would close an important treatment gap, but it would not by itself offset the looming 2028 loss of US exclusivity for dolutegravir. HIV remains central to GSK: the division generated £1.8 billion in first-quarter sales, about 24% of the group total, and grew 10% at constant exchange rates.
June 22, 2026
GSK drops 3% for the week even after U.S. nod for Utebzi
·

GSK drops 3% for the week even after U.S. nod for Utebzi

GSK closed Friday at 1,925.5 pence, up 0.13% on the day but down 2.95% for the week. The stock lagged the FTSE 100 by about two percentage points over the week. Shares fell after the pipeline win. Investors look to be focusing less on regulatory progress and more on when GSK can launch, how products will sell, and how much its recent acquisitions cost. The approval gives a boost to GSK’s infectious-disease business, but there’s no big sales pop yet.
June 20, 2026
GSK shares bounce after FDA nod for Utebzi
·

GSK shares bounce after FDA nod for Utebzi

GSK shares pushed higher in London Friday morning after the company got U.S. approval for Utebzi, an oral antibiotic meant for adults with complicated urinary tract infections who don’t have other oral treatment options. The stock opened at 1,926 pence and reached 1,943 pence. Why it matters: Carbapenems are strong antibiotics, but until now, patients could only get them by IV. GSK says over 3 million tough cases hit the U.S. yearly, and failure rates can reach 34%.
June 19, 2026
GSK Shares Gain After Arexvy Approval for More Adults in Japan
·

GSK Stock Falls 1.9% Despite FDA Approval for Oral Antibiotic Utebzi

GSK shares fell nearly 2% on Thursday despite U.S. approval for Utebzi, a new oral antibiotic aimed at hard-to-treat urinary tract infections. The stock was down 37.5 pence at 1,935 pence as of 15:06 BST, compared with a 0.87% decline in the FTSE 100 shortly before 15:00. The broader market weakened after the Bank of England held rates at 3.75% and the U.S. Federal Reserve signalled a more hawkish policy path. The regulatory decision removes a significant development risk for GSK’s anti-infectives pipeline. Still, the market response was restrained. Investors now need evidence on pricing, hospital adoption and how quickly prescriptions can turn into material revenue.
June 18, 2026
GSK stock ticks up in London while investors look at Nuvalent cancer deal
··

GSK stock ticks up in London while investors look at Nuvalent cancer deal

GSK shares traded higher in London on Wednesday, even as the UK blue-chip index edged down. Investors kept looking at the drugmaker’s plan to strengthen its cancer unit with a planned buyout of U.S. biotech Nuvalent. GSK shares traded at 1,962p, up 0.62%, at 12:41 p.m. in London after opening at 1,948.5p. The FTSE 100 slipped 0.14% earlier as traders looked at UK inflation data ahead of the Bank of England’s rate call.
June 17, 2026
GSK steady at 1,960p as FTSE 100 ticks higher, eyes on Nuvalent deal and July plans
·

GSK steady at 1,960p as FTSE 100 ticks higher, eyes on Nuvalent deal and July plans

London, June 16, 2026, 13:08 BST. GSK plc closed flat in London on Tuesday. AJ Bell showed the stock at 1,959.50p to sell and 1,960.00p to buy, a slim gain of 1.50p, or 0.08%. The FTSE 100 outpaced it, climbing around 0.6% to 10,490.35 as banks and industrials moved higher and weaker oil prices lifted sentiment. GSK didn’t move with the index’s rally—it wasn’t market selling, just the shares missing out.
June 16, 2026
1 2